ABTL 0812

Drug Profile

ABTL 0812

Alternative Names: ABTL-0812; ABTL0812 (lipid analog therapeutic molecule); LP-10218

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Lipopharma
  • Developer Ability Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Autophagy inhibitors; Autophagy stimulants; Gene expression inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Neuroblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer; Lung cancer
  • Phase I Solid tumours
  • Preclinical Pancreatic cancer

Most Recent Events

  • 14 Dec 2016 ABTL 0812 receives Orphan Drug status for Pancreatic cancer in USA
  • 22 Nov 2016 Phase-II clinical trials in Endometrial cancer (Combination therapy, First-line therapy, Late-stage disease, Recurrent) in Spain (PO)
  • 22 Nov 2016 Phase-II clinical trials in Lung cancer (Combination therapy, First-line therapy, Late-stage disease, Recurrent) in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top